Esomeprazole magnesium 2.5 mg / 1 For Suspension 30 For Suspension
Comprehensive product details for sourcing and verification.
| NDC 11 | 69097-0507-31 |
|---|---|
| Product NDC | 69097-0507 |
| Generic Drug Name | Esomeprazole magnesium |
| Brand Name | Esomeprazole magnesium |
| Manufacturer | Cipla USA Inc. |
| Strength | 2.5 mg / 1 |
| Dosage Form | For Suspension |
| Drug Type | Oral |
| Package Quantity | 30 For Suspension |
| Package Description | 30 FOR SUSPENSION in 1 CARTON (69097-507-31) |
| Active Ingredients | Esomeprazole Magnesium Dihydrate |
| Marketing Category | ANDA |
Unless explicitly stated in writing, no direct affiliation, sponsorship, or endorsement by individual product manufacturers with Premium Rx National, LLC should be implied. All brand names, trade names, and trademarks are the property of their respective owners and are presented solely for accurate product identification and informational reference.
NDC snapshot
Esomeprazole magnesium 2.5 mg / 1 For Suspension is tracked under NDC 69097-0507-31 and rolls up into product family 69097-0507. Use this page to confirm the exact presentation before moving into related family or manufacturer pathways.
- Package configuration: 30 For Suspension.
- Manufacturer: Cipla USA Inc..
- Dosage form: For Suspension.
- Family size: 1 active presentation.
Click a tag to refine the catalog view around this exact presentation.
Official references
Use official labeling and directory references to confirm presentation details while your team reviews the PRN catalog entry and related sourcing paths.
Esomeprazole magnesium 2.5 mg / 1 For Suspension 30 For Suspension, NDC 69097-0507-31, is a Cipla USA Inc. 2.5 mg / 1 for suspension presentation packaged as 30 For Suspension.
NDC search formats
- Canonical NDC 11: 69097-0507-31.
- Digits-only NDC 11: 69097050731.
- Possible 10-digit display format: 69097-507-31 (6909750731).
Helpful product links
- Search by brand name: Esomeprazole magnesium.
- Exact NDC 11: 69097-0507-31.
- Product family NDC: 69097-0507.
